<DOC>
	<DOCNO>NCT00154687</DOCNO>
	<brief_summary>The purpose study evaluate efficacy Weekly TP-HDFL advance transitional cell carcinoma term response rate overall survival .</brief_summary>
	<brief_title>Weekly TP-HDFL Treatment Advanced TCC</brief_title>
	<detailed_description>Transitional cell carcinoma ( TCC ) urothelium , include bladder , ureter , renal pelvis TCCs , lethal urology malignancy Taiwan . In 1995 , approximately 1,300 new case TCC diagnose Taiwan 600 patient die disease . Advanced TCC moderately chemosensitive disease . A combination methotrexate , vinblastine , cisplatin without doxorubicin ( M-VAC CMV ) widely use since 1980s . Despite response rate high 40-70 % , survival patient slightly increase median 7 9 month treat supportive care cisplatin alone median 12 month cisplatin-based combination chemotherapy . One reason poor treatment result inevitable treatment-related toxicity relate conventional systemic chemotherapy .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Pathology proven TCC Recurrent metastatic TCC Muscleinvasive TCC 2 . Measurable disease 3 . Age＞18 4 . KPS＞60﹪ 5 . Creatinine clearance＞35ml/min , 6 . AST/ALT &lt; = 3.5times upper limit normal reference value 7 . Bilirubin &lt; = 2.0 mg/dl 8 . WBC &gt; = 4,000/mm3 , PLT &gt; = 100,000/mm3 9 . Written inform consent 1 . Previous systemic chemo allow 2 . TG ＜70mg/dl 3 . CNS metastasis 4 . Life expectancy le 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>Combination , Chemotherapy , transitional cell carcinoma</keyword>
</DOC>